TNBC, TRIPLE NEGATIVE BREAST CANCER
Clinical trials for TNBC, TRIPLE NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new TNBC, TRIPLE NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a targeted combo shrink breast cancer tumors with fewer side effects?
Disease control Not yet recruitingThis study tests a two-drug combination (sacituzumab govitecan and tislelizumab) given before surgery to people with early-stage triple-negative breast cancer. The goal is to see if this treatment can shrink tumors enough to allow a less aggressive approach, based on specific mar…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: First Hospital of China Medical University • Aim: Disease control
Last updated May 26, 2026 05:12 UTC
-
New hope for advanced breast cancer: fluzoparib maintenance after platinum success
Disease control Not yet recruitingThis study tests a drug called fluzoparib as a maintenance treatment for people with advanced triple-negative breast cancer (TNBC) whose disease was controlled by platinum-based chemotherapy. The goal is to see if fluzoparib can delay cancer growth. The study includes patients wi…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 26, 2026 05:12 UTC
-
Immunotherapy combo shows promise in tough breast cancer trial
Disease control Not yet recruitingThis study tests whether adding the immunotherapy drug toripalimab to chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. About 216 adults with early-stage or locally advanced disease will receive either toripalimab plus one of two chem…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated May 26, 2026 05:11 UTC
-
New targeted drug SC-101 takes aim at Hard-to-Treat breast cancers
Disease control Not yet recruitingThis study tests a new drug called SC-101 in people with advanced breast cancer that has a specific gene change (NECTIN4). The goal is to see if the drug can shrink tumors and how safe it is. About 120 adults aged 18-75 with triple-negative or HR+ breast cancer will take part.
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Tianjin ConjuStar Biologics Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 05:05 UTC
-
New combo aims to reignite immune response in tough breast cancer
Disease control Not yet recruitingThis study tests whether adding radiation and a drug called axatilimab can help the immunotherapy pembrolizumab work better in people with metastatic triple-negative breast cancer (TNBC) who have already tried immunotherapy. About 34 adults with at least two measurable tumors wil…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Stephen Shiao • Aim: Disease control
Last updated May 26, 2026 04:35 UTC
-
New hope for hard-to-treat breast cancer: drug duo targets PD-L1 positive tumors
Disease control Not yet recruitingThis study tests a combination of two drugs, Sacituzumab Tirumotecan and Toripalimab, as a first treatment for people with a specific type of advanced triple-negative breast cancer that has a protein called PD-L1. The goal is to see if the combo shrinks tumors and how safe it is.…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 26, 2026 04:35 UTC
-
Gut bacteria pill joins forces with chemo to fight aggressive breast cancer
Disease control Not yet recruitingThis study tests whether adding a live bacteria pill (MO-03) to standard chemotherapy and immunotherapy can improve outcomes for people with early-stage triple-negative breast cancer. About 50 participants will take the pill twice daily until surgery. The main goal is to see if t…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Yuan Yuan • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New drug combo targets tough breast cancer in early trial
Disease control Not yet recruitingThis study tests a combination of two drugs, inavolisib and eribulin, in people with advanced triple-negative breast cancer that has a specific genetic change (PIK3CA mutation) and has not responded to at least one prior treatment. The goal is to see if the combination shrinks tu…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Hu Hai • Aim: Disease control
Last updated May 18, 2026 12:04 UTC
-
New study to reveal best Pre-Surgery treatment for aggressive breast cancer
Knowledge-focused Not yet recruitingThis study looks back at data from 201 people with triple-negative breast cancer who received chemotherapy or immunotherapy before surgery. The goal is to see which treatment leads to a complete response (no cancer left) and what factors affect success. It does not test a new tre…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Knowledge-focused
Last updated May 26, 2026 05:06 UTC